Gilead Appoints Dr. Muzammil M. Mansuri as Senior Vice President, Research and Development Strategy and Corporate Development
April 27 2011 - 4:05PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today the
appointment of Muzammil M. (“Muz”) Mansuri, PhD, to Senior Vice
President, Research and Development Strategy and Corporate
Development, a role that expands his current responsibilities as
Senior Vice President, Research and Development Strategy to include
leadership of Corporate Development and Alliance Management. In
this new role, Dr. Mansuri will help to define and implement
Gilead’s research and development strategy, explore new business
opportunities, drive strategic and portfolio management activities,
and build and manage Gilead’s alliances, partnerships and
acquisitions. Dr. Mansuri will report both to John F. Milligan,
PhD, Gilead’s President and Chief Operating Officer, and to Norbert
W. Bischofberger, PhD, Gilead’s Executive Vice President, Research
and Development and Chief Scientific Officer.
Dr. Mansuri joined Gilead in July 2010, following the company’s
acquisition of CGI Pharmaceuticals, Inc. Prior to joining Gilead,
Dr. Mansuri served as the Chief Executive Officer or Chief
Operating Officer at several small biotechnology companies,
including CGI, BIKAM Pharmaceuticals, Sequoia Pharmaceuticals, GPC
Biotech and Mitotix, Inc. He also was a general partner with
Flagship Ventures and served on the boards of CGI, AVEO
Pharmaceuticals, BG Medicine and Adaptive Therapeutics. Earlier in
his career, Dr. Mansuri spent 10 years with Bristol-Myers Squibb,
where he initiated antiretroviral chemistry efforts for d4T and led
the project team that developed the compound for the treatment of
HIV.
“Since joining Gilead, Muz has played a key role in efforts to
expand our pipeline into the areas of oncology and inflammation
with the acquisitions of Arresto Biosciences and Calistoga
Pharmaceuticals,” said Dr. Milligan. “His broad knowledge of
research and clinical development will be instrumental as we
evaluate opportunities to partner with other companies and
institutions to advance novel therapies in areas of significant
unmet need.”
Dr. Mansuri received his bachelor of science and doctoral
degrees from University College London, University of London, and
completed post-doctoral fellowships at Columbia University and the
University of California, Los Angeles.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
For more information on Gilead Sciences, please
visit www.gilead.com or call the Gilead Public Affairs Department
at 1-800-GILEAD-5 (1-800-445-3235).
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024